Endovastec™ Attends the Third CMDA-CACVS Annual Academic Congress

Beijing, China — Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (“Endovastec™”) recently attended and presented at the Third CMA-CACVS Annual Academic Congress, organized by the Chinese Medical Doctor Association (CMDA) and the Chinese Association of Cardiovascular Surgeons (CACVS). Endovastec™ held a pre-seminar on new strategies for lower extremity arterial diseases titled “Focus on PAD” (peripheral arterial disease) and a special satellite session themed “An extraordinary probe: Abdominal endovascular aneurysm repair (EVAR)” showcasing the Reewarm™ PTX Drug-Coated Balloon PTA Catheter and the Minos™ Abdominal Aortic Stent-Graft and Delivery System.

During the “Focus on PAD” pre-seminar, Prof. Qingle Li from the Department of Vascular Surgery of Peking University People’s Hospital, and Prof. Sheng Wang from the Department of Vascular Surgery of Anzhen Hospital, affiliated to the Capital Medical University, gave a detailed report on the drug-coated balloon and relevant clinical studies. They shared the long-term follow-up results regarding the safety and efficacy of paclitaxel drug-coated balloons, and compared the pros and cons of the drug-coated balloons. They concluded that the effectiveness of paclitaxel drug-coated balloons in the treatment of lower extremity arterial lesions—including complex ones—has been verified by data and that their efficiency could be further improved by more efficient drug delivery techniques.

An example of this is the Reewarm® PTX DCB Catheter, which uses paclitaxel and iopromide as the coating drug and proven ultrasonic micro-atomizing spray technology, which allows for a more uniform, stable and precise release. The Reewarm® PTX DCB Catheter is used for balloon dilation of the popliteal artery during percutaneous transluminal angioplasty (PTA). The unique coating formulation and spraying process of the Reewarm® PTX DCB Catheter enables precise drug release and ensures a steady and sufficient drug supply at the lesion site, whilst reducing residual drug in the blood and other non-target lesion sites, hence lowering the incidence of adverse reactions. The PTX DCB Catheter features small drug particles and a high vessel wall absorption rate, reducing the risk of distal embolism that could be caused by larger particles.

At the session, Endovastec™ provided an analysis of clinical data for the Reewarm® PTX DCB Catheter, which showed that the incidence of adverse events at 12 months after the surgery was significantly lower than that of the control group (23.0% vs. 38.0%, P<0.05). They noted that the 2-year follow-up result revealed the mortality rate of patients in the Reewarm® PTX DCB Catheter group was statistically significantly lower than that of the control group.

During the special satellite session on EVAR, the participating experts shared their insights on “Single-center clinical data and indication analysis of the Minos® Stent Graft System”. They acknowledged the performance of the Minos® Stent Graft System in complex abdominal aortic aneurysm conditions such as short aortic neck, access artery stenosis, and tortuous aortic neck, etc. The experts noted that the single-center clinical data showed favorable clinical outcomes of the Minos® Stent Graft System for interventional therapy of subrenal abdominal aortic aneurysms, and that comparison of pre- and post-market data of the Minos® Stent Graft System further validated its safety and efficacy.

About Endovastec™

Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™), is a subsidiary of MicroPort Scientific Corporation (MicroPort®, 00853.HK), and was founded in Shanghai SIMZ Century Medicine Park in 2012. Endovastec™ was granted Shanghai High-tech Enterprises, Shanghai Science and Technology Little Giant Enterprise, and the first batch of Specialized and New “Little Giant” Enterprise, AAA-level Credit Enterprise and Multinational R&D Center in China. Endovastec™ was listed on the STAR Market (Stock code: 688016) of the Shanghai Stock Exchange on July 22, 2019.

About EVAR

In the development of EVAR techniques, anatomic patterns such as access artery stenosis and short aortic neck have presented major clinical challenges as they can cause access artery complications. Through a combination of material, structure and process optimization, Minos® combines the classic and traditional stent graft structure with a low profile (small delivery OD) delivery sheath, allowing EVAR to be applied in cases with twisted and narrow access arteries. It presents a unique advantage in treating complex abdominal aortic aneurysms, especially in cases with access artery stenosis, tortuous aortic neck and short aortic neck, therefore benefiting a greater number of patients.